PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting

PRINCETON, N.J., Nov. 4, 2010 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that more than twenty posters will be presented by Company scientists at the 2010 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition being held from November 14 -18 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Leading PharmaNet's delegation at AAPS will be Riaz Bandali, President, Early Stage Development, who is responsible for the Company's Phase I clinics and bioanalytical laboratories. Mr. Bandali and other PharmaNet experts will be at booth 1519 to discuss the Company's industry-leading bioanalytical capacity, the Company's offerings of more than 1000 validated methods and its custom method development and validation, bioanalytical mass spectrometry, and immunochemistry services.

Attendees are invited to attend the PharmaNet poster presentations:  

Monday, November 15, 2010, 13:00 – 17:00 Exhibit Hall B1

Quantitative Determination of Alendronate Sodium in Human Plasma Using a Validated LCMSMS Method: Application to Clinical Pharmacokinetic Studies, (M1500)

Tuesday, November 16, 2010, 8:00 – 12:00 Exhibit Hall B1

Leuprolide: A Sensitive LCMSMS Method for the Analysis of a Large Molecule, (T2245)

Development and Validation of a Dried Blood Spot Assay for the Determination of Midazolam in Human Whole Blood by LCMSMS, (T2253)

Importance of Incurred Samples Reanalysis to Assess the Reproducibility of Exemestane Assay, (T2288)

Specific, Selective and Robust Determination of Quaternary Ammonium Compound Scopolamine N-Butyl in Human Plasma by LCMSMS, (T2252)

Innovative Determination of Unbound Docetaxel in Human Plasma using a Filtration Device, (T2271)

A Robust and Specific Analytical Method for the Determination of Dienogest, a Hormone Replacement Therapy, (T2300)

Derivatization of Phenolic Co-Extracts for Better Sensitivity and Selectivity of Etonogestrel Assay at Low Picograms Levels, (T2282)

Robust Pharmacokinetic Characterization of Methylprednisolone in Normal Healthy Volunteers using a Highly Sensitive Analytical Method, (T2314)

A validated LC-MS/MS Method for the Simultaneous Determination of the Anti-Cancer Agent Capecitabine and its Metabolite, 5'-Deoxy-5-fluorocytidine (5'-DFCR) in Human Plasma, (2287)

Brivanib Alaninate Can Be Safely Co-Administered with CYP2C8 Substrates in Humans, (T2380)

Development of a Single Method for the Determination of Buprenorphine, Norbuprenorphine, and their Glucuronide Metabolites in Human Plasma Using LC/MS/MS, (T2258)

High Resolution Accurate Mass LC-MS for In Vivo Fast PK Studies, (T2319)

On-the-Fly Metabolite ID & Quantitation During Fast PK Bioanalysis Using High Resolution Mass Spectrometry, (T2285)

A Multi-Point Staggered Injection Technique for LCMSMS Bioanalysis: Accounting for Standard Curve Divergence During Sample Analysis, (T2325)

Comparative Analysis of Buprenorphine and Oxycodone in Human Dried Blood Using LCMSMS, (T2341)

Optimizing Tissue Analysis for LC-MS/MS in Support of Drug Distribution Studies, (T2332)

Integration of Hamilton Robotics into a LIMS Platform in Support of Regulated and Discovery Bioanalysis, (T2333)

Development of Liquid Handler Pipetting Settings for Sample Additions in Biological Matrices to Assay Plates for Quantitation Assays and Anti-Drug Antibody Assays, (T2438)

Tuesday, November 16, 2010, 13:00 – 17:00 Exhibit Hall B1

Development and Optimization of an Immunoassay for Quantifying Glucagon in Cyano Monkey Serum, (T3277)

Wednesday, November 17, 2010, 13:00 – 17:00 Exhibit Hall B1

High-Throughput Drug-Protein Binding Assay in Whole Blood, Plasma, and Brain Tissue, (W5309)

Thursday, November 18, 2010, 8:00 – 12:00 Exhibit Hall B1

Method Development of an Assay for the Quantitation of an Adsorption-Prone Compound in Human Urine, (R6348)

A Rapid Simple Validated LCMSMS Method for Analysis of Bilastine in Human Plasma and Urine, (R6359) 

Use of Hemolysed Plasma for Matrix Effect Evaluation in the Validation of a LCMSMS Method, (R6368)

For more information about PharmaNet's comprehensive range of services, please visit us at booth 1519. Alternatively, please email [email protected] or visit www.pharmanet.com.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.

SOURCE PharmaNet Development Group, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED